PREgnancy and FERtility Registry

Conditions studied

Breast Neoplasms, Pregnancy, Fertility Preservation

About this study

The PREgnancy and FERtility (PREFER) study is a comprehensive program aiming to optimize care and improve knowledge around the topics of fertility preservation and pregnancy issues in young breast cancer patients. The program was initiated at the National Institute for Cancer Research, IRCCS AOU San Martino - IST in Genova (Liguria Region, Italy) and then it has been spread to other Italian Institutions under the umbrella of the Gruppo Italiano Mammella (GIM) study group. It is composed of two distinctive studies, one assessing fertility (i.e. PREFER-FERTILITY) and the other pregnancy (PREFER-PREGNANCY) issues. Hence, two different study protocols were developed under the umbrella of the PREFER registry. PREFER-FERTILITY aims to obtain and centralize data about the preferences and choices of young cancer patients on the fertility preservation strategies available in Italy. Furthermore, it aims to assess the outcomes of patients undergoing one or more strategies for fertility preservation in terms of success of the techniques (i.e. recovery of ovarian function, number of cryopreserved oocytes, post-treatment pregnancies) and safety (i.e. long-term survival outcomes). PREFER-PREGNANCY has two main objectives: 1) to obtain and centralize data on the management of breast cancer diagnosed during pregnancy, the obstetrical and paediatric care of children born after prior in utero exposure to anticancer treatments, and the long-term survival outcomes of these patients; 2) to obtain and centralize data on the clinical outcomes of breast cancer survivors that achieve a pregnancy after prior diagnosis and treatment of breast cancer.

Primary outcomes

• Rate of patients interested in the available strategies for fertility preservation (15 years)
• Rate of patients undergoing the different strategies for fertility preservation (15 years)
• Type of strategies for fertility preservation proposed by oncologists (15 years)
• Reasons for refusal of the available strategies for fertility preservation (15 years)
• Type of anticancer therapies administered during pregnancy (15 years)
• Safety: pregnancy complications (15 years)
• Safety: incidence of adverse events (15 years)
• Disease-free survival (15 years)

Eligibility information

Study locations

• Ospedale Cardinal Massaia, Asti, Asti Italy
• Presidio Ospedaliero 'Antonio Perrino', Brindisi, BR 72100 Italy
• AOU di Cagliari Strada, Monserrato, Cagliari Italy
• Azienda Ospedaliera S. Croce e Carle, Cuneo, CN 12100 Italy
• Arcispedale S. Anna - A.O.U. di Ferrara, Cona, FE 44124 Italy
• Irccs Aou San Martino - Ist, Genoa, GE 16132 Italy
• Ospedale Vito Fazzi, Lecce, LE 73100 Italy
• Ospedale Unico Versilia, Lido di Camaiore, LU 55041 Italy
• Azienda Ospedaliera Carlo Poma, Mantua, MN 46100 Italy
• Ospedale 'Guglielmo da Saliceto', Piacenza, PC 29121 Italy

Showing 10 of 23 reported sites. See the official listing for all locations.